Benefits
Multiple myeloma chemotherapy immunomodulation
Multiple myeloma patients undergoing high-dose chemotherapy and autologous stem cell transplantation received AndoSan AbM-based mushroom extract 60 mL/day versus placebo for ~7 weeks. Outcomes assessed cytokine/chemokine/growth factor changes, immune gene expression, and stem cell mononuclear cell subsets. Methodologically rigorous oncology immunomodulation evidence.
NSCLC perioperative immune modulation (multicenter pilot)
In a non-small-cell lung cancer perioperative pilot using a multivitamin complex containing AbM, there was significantly better preservation of T cells and B cells, with greater reduction in monocytes. Surgery patients are immunologically vulnerable, and preserved lymphocyte counts during the perioperative window may have downstream clinical implications.
NLRP3 inflammasome activation
AbM water extracts enhance IL-1beta production and activate the NLRP3 inflammasome in human THP-1 macrophages. Innate immune activation mechanism, relevant to the immune-support indication and the context-dependent immunomodulation pattern.
IBD cytokine modulation (Førland 2011)
In ulcerative colitis and Crohn's patients on AndoSan, cytokines MIP-1beta, MCP-1, IL-8, IL-1beta, G-CSF, IL-17, GM-CSF, and IL-2 were significantly reduced versus baseline. Notably, this is anti-inflammatory in vivo despite the pro-inflammatory in vitro pattern, illustrating context-dependent immunomodulation.
Antitumor mechanism review
A comprehensive review of A. blazei + Hericium erinaceus + Grifola frondosa antitumor mechanisms describes multi-mechanism action: beta-glucan-Dectin-1 binding, NK cell activation, Th1 cytotoxic cell induction, anti-angiogenic and anti-metastatic effects, and chemotherapy enhancement with side-effect reduction.
β-glucan-protein complex antitumor
A (1->6)-beta-D-glucan-protein complex (FIII-2-b) isolated from AbM 'Himematsutake' showed inhibitory action on Meth A fibrosarcoma in mice. Foundational preclinical mechanism work for the AbM antitumor research program.
Honest framing — context-dependent immunomodulation
AbM differentially stimulates pro-inflammatory cytokine production in human monocytes and endothelial cells in vitro. However, oral intake in IBD patients reduces inflammatory cytokines in vivo. Pro-inflammatory in vitro versus immunosuppressive in vivo with oral intake, an important framing for autoimmune-condition caution and for understanding the apparent paradox between cellular and clinical findings.
Mechanism of action
β-(1→6)-D-glucan-protein complex (FIII-2-b)
Distinguishing structural feature among medicinal mushroom polysaccharides - FIII-2-b isolated from Himematsutake. Binds Dectin-1 on innate immune cells driving the immune-activation signal.
NLRP3 inflammasome activation + IL-1β production
AbM water extracts activate the NLRP3 inflammasome in human THP-1 macrophages with IL-1beta production. Innate immune mechanism contributing to the cytokine effects.
Th1 cytotoxic cell + NK cell activation
Cellular immunity mechanism — Th1 cytotoxic T cell and NK cell activation drives the proposed antitumor effects and contributes to the chemotherapy-enhancement and immune-preservation observations.
Anti-angiogenic and anti-metastatic effects
Indirect anti-tumor mechanisms via inhibition of tumor neovascularization and metastatic seeding. Preclinical mechanism framework for the oncology adjunct positioning.
Chemotherapy enhancement and side-effect reduction
Preclinical evidence for chemotherapy enhancement combined with reduced chemotherapy-related side effects — the mechanistic rationale for the NCT00970021 multiple myeloma trial design.
Context-dependent immunomodulation (paradox resolution)
Pro-inflammatory in vitro vs immunosuppressive in vivo with oral intake — likely reflecting differences between direct cellular exposure and the systemic effects of orally-absorbed metabolites or microbiome-mediated effects. Distinctive feature of AbM compared to many medicinal mushrooms.
Clinical trials
Randomized double-blind phase 2 trial at Ullevaal University Hospital.
Clinical population described in trial publication.
Randomized double-blind phase 2 trial at Ullevaal University Hospital. Multiple myeloma patients undergoing high-dose chemotherapy + autologous stem cell transplantation. AndoSan™ AbM-based mushroom extract 60 mL/day for ~7 weeks vs placebo. Primary endpoints: cytokine/chemokine/growth factor changes, immune gene expression, stem cell mononuclear cell subsets. Status: completed. Pivotal oncology immunomodulation trial.
Randomized double-blind placebo-controlled multicenter pilot in non-small-cell lung cancer perioperative immune modulation.
Clinical population described in trial publication.
Randomized double-blind placebo-controlled multicenter pilot in non-small-cell lung cancer perioperative immune modulation. Multivitamin complex containing AbM. Significantly preserved T cells (P=0.026) and B cells (P=0.001), with greater reduction in monocytes (P=0.031). Lymphocyte preservation during the immunologically vulnerable perioperative window.
Clinical evidence on Agaricus blazei Murill (AbM / Himematsutake / Royal Sun Mushroom) for the indications and outcomes described.
Clinical population described in trial publication.
Førland DT et al. 2011 (Scand J Immunol 73:66-75). UC and Crohn's patients on AndoSan: significantly reduced MIP-1β, MCP-1, IL-8, IL-1β, G-CSF, IL-17, GM-CSF, IL-2 vs day 0. In vivo anti-inflammatory effect contrasting with in vitro pro-inflammatory pattern.